Clinical Trial Update: Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating toripalimab in combination with capecitabine as postoperative adjuvant therapy for resectable extrahepatic biliary tract cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Distal Cholangiocarcinoma
• Gallbladder Cancer
• Hilar Cholangiocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Gallbladder Cancer, Hilar Cholangiocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING